David B Clifford1. 1. Department of Neurology, Washington University, St. Louis, Missouri, USA.
Abstract
PURPOSE OF REVIEW: This manuscript reviews current reports about clinical aspects of immune reconstitution inflammatory syndrome (IRIS), with a particular emphasis on IRIS in the setting of progressive multifocal leukoencephalopathy (PML) and to a lesser extent on cryptococcal meningitis and HIV. RECENT FINDINGS: PML prognosis has been radically improved, as it has become possible to provide immune reconstitution, although some remaining morbidity and mortality results from excess inflammation. Similar pathologic responses are seen less often, but remain clinically important in cryptococcal meningitis, and HIV. Early diagnosis and active management of PML results in optimal outcomes with survival of 75% or higher in multiple recent series. These finding apply both to natalizumab and HIV-associated PML. Cryptococcal meningitis is frequently complicated by IRIS, and early treatment with antifungal therapy preceding HIV therapy provides optimal outcomes. HIV IRIS is reduced by early therapy, which is now recommended, but even on therapy, chronic dysregulated immune responses may play important roles in ongoing HIV-associated neurocognitive disease (HAND), which is common, as well as rare but more dramatic subacute encephalopathies. SUMMARY: The clinician must actively monitor and treat both opportunistic infection and the inflammatory response that is essential to recovery but may itself augment disease and injury.
PURPOSE OF REVIEW: This manuscript reviews current reports about clinical aspects of immune reconstitution inflammatory syndrome (IRIS), with a particular emphasis on IRIS in the setting of progressive multifocal leukoencephalopathy (PML) and to a lesser extent on cryptococcal meningitis and HIV. RECENT FINDINGS: PML prognosis has been radically improved, as it has become possible to provide immune reconstitution, although some remaining morbidity and mortality results from excess inflammation. Similar pathologic responses are seen less often, but remain clinically important in cryptococcal meningitis, and HIV. Early diagnosis and active management of PML results in optimal outcomes with survival of 75% or higher in multiple recent series. These finding apply both to natalizumab and HIV-associated PML. Cryptococcal meningitis is frequently complicated by IRIS, and early treatment with antifungal therapy preceding HIV therapy provides optimal outcomes. HIV IRIS is reduced by early therapy, which is now recommended, but even on therapy, chronic dysregulated immune responses may play important roles in ongoing HIV-associated neurocognitive disease (HAND), which is common, as well as rare but more dramatic subacute encephalopathies. SUMMARY: The clinician must actively monitor and treat both opportunistic infection and the inflammatory response that is essential to recovery but may itself augment disease and injury.
Authors: Patricia Escandón; Jairo Lizarazo; Clara Ines Agudelo; Tom Chiller; Elizabeth Castañeda Journal: Med Mycol Date: 2013-04-23 Impact factor: 4.076
Authors: Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Robert E Lenkinski; Igor J Koralnik Journal: Neurology Date: 2012-08-22 Impact factor: 9.910
Authors: Joan Rugemalila; Venance P Maro; Gibson Kapanda; Arnold J Ndaro; Joseph N Jarvis Journal: Trop Med Int Health Date: 2013-09 Impact factor: 2.622
Authors: M J D Post; M M Thurnher; D B Clifford; A Nath; R G Gonzalez; R K Gupta; K K Post Journal: AJNR Am J Neuroradiol Date: 2012-07-12 Impact factor: 3.825
Authors: M J D Post; M M Thurnher; D B Clifford; A Nath; R G Gonzalez; R K Gupta; K K Post Journal: AJNR Am J Neuroradiol Date: 2012-07-12 Impact factor: 3.825
Authors: Brian C Haynes; Michael L Skowyra; Sarah J Spencer; Stacey R Gish; Matthew Williams; Elizabeth P Held; Michael R Brent; Tamara L Doering Journal: PLoS Pathog Date: 2011-12-08 Impact factor: 6.823